Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab vs Investigator's Choice in R/R Mantle Cell Lymphoma
NCT06084936Phase 3Recruiting
- Sponsor
- Roche
- Start
- Oct 2023
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of glofitamab in mantle cell lymphoma (MCL), sponsored by Roche. Started Oct 2023; status: recruiting.
02
Drugs
glofitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06084936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084936.